NewLimit Secures $130M Series B Funding Led by Kleiner Perkins

The funding affirms the biotech’s potential in longevity research and strengthens interest in epigenomic advances within the industry.

NewLimit, the biotechnology firm co-founded by Brian Armstrong, CEO of Coinbase, received significant $130 million in Series B funding, led by Kleiner Perkins. The company now stands at a valuation of $810 million as of May 6, 2025.

Key figures in this venture include Armstrong, who serves as an investor and board member, alongside Jacob Kimmel and Blake Byers, who complete the leadership team. Kleiner Perkins, with partner Ilya Fushman, has championed NewLimit’s advance in anti-aging research.

“The technology is advancing anti-aging research at an unprecedented speed in the industry by combining large-scale genomics with cutting-edge AI.” —Ilya Fushman, Partner, Kleiner Perkins

The funding underscores a growing interest in biotechnology, driven by innovations in epigenetic reprogramming. This approach seeks to reverse cellular aging, highlighting investments in future longevity technologies.

The financial implications indicate a rising attractiveness of biotech ventures, especially those into age-extending solutions. The backing by venture capital, including Founders Fund and Khosla Ventures, underpins this trend.

Potential outcomes relate to breakthroughs in genomics and AI, suggesting impactful age-reversal solutions. NewLimit’s approach, combining AI with single-cell sequencing, marks a significant step in reducing research costs, promising future advancements in longevity.